Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy

Front Immunol. 2021 Dec 6:12:789473. doi: 10.3389/fimmu.2021.789473. eCollection 2021.
No abstract available

Keywords: IDO; TDO; cancer immunology; immunometabolism; immunotherapy.

Publication types

  • Editorial
  • Introductory Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Immunotherapy* / adverse effects
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / antagonists & inhibitors*
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Neoplasms / immunology
  • Signal Transduction
  • Tryptophan Oxygenase / antagonists & inhibitors*
  • Tryptophan Oxygenase / metabolism
  • Tumor Escape / drug effects
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • IDO1 protein, human
  • IDO2 protein, human
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Tryptophan Oxygenase